Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces Dosing Of First Participant In Global Phase 1/1b Study Of ZL-1503, An IL-13/IL-31R Bispecific Antibody For Treatment Of Atopic Dermatitis

Dec 8 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB ANNOUNCES DOSING OF FIRST PARTICIPANT IN GLOBAL PHASE 1/1B STUDY OF ZL-1503, AN IL-13/IL-31R BISPECIFIC ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS

Source text: ID:nBw4HYDdDa

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news